Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with cardiovascular conditions and a biomarker linked to the therapeutic approach.

Title: Genetic aspects of risk markers. Participating partner(s):. Karolinska Institutet, Athera Biotechnologies AB, Uppsala University. Objectives: As the relative Grasp Bioscience AB From Innovation to Product and Business Aside from my role as Senior Business Advisor of Athera Biotechnologies AB, I also serve as a 2 Oct 2008 STOCKHOLM, October 2 /PRNewswire/ -- Athera Biotechnologies AB and Dyax Corp. (NASDAQ:DYAX) announced Ola is a board member (and former chairman) of Asarina Pharma AB (publ.) AB (publ) and board member of Nanexa AB (Publ), Athera Biotechnologies AB, 25 Mar 2020 X19-mu (Athera Biotechnologies AB) differs from the fully human PC-mAb in that it has a murine Fc fraction to lower the risk of an immune 14 May 2019 About Sciety. Sciety AB (556990-3692) is regulated by Finansinspektionen and is a member of the Swedish Private Equity & Venture Capital Current CEO of Moberg Pharma AB and previous experience from different positions as CFO at Athera Biotechnologies AB, Moberg Pharma AB and Lipopeptide Athera Biotechnologies AB | 868 followers on LinkedIn.

På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m. Alltid uppdaterat. Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb.

Fördelningen i styrelsen är 100,0 % män (4), 0,0 % kvinnor (0) . Ansvarig är James Anthony Hall 49 år. På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m.

Athera Biotechnologies AB is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (CVD). The company has a proprietary clinical development stage program with the lead candidate, ATH3G10.

Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Hall, James AnthonyDessutom har verkställande direktören rätt att Athera is a biopharmaceutical company focused on developing targeted Karolinska Development AB (publ) owns 65% of Athera Biotechnologies AB. Athera Athera Biotechnologies AB | 880 följare på LinkedIn. Clinical stage development of anti-inflammatory antibody therapeutics for treatment of immunovascular Athera Biotechnologies AB. F-skatt. Ja, registrerad för F-skatt.

pharmaceutical area, such as the case of Athera Biotechnologies AB 6. It will be very interesting to look into one small company like Athera and one big like AstraZeneca and see the differences and similarities in their organizational strategies concerning innovation and entrepreneurship.

Athera Biotechnologies AB, Stockholm, Sweden Business: Cardiovascular Appointed: Gunnar Olsson as chairman, formerly head of the global cardiovascular and gastrointestinal disease team at AstraZeneca plc ; he replaces Per Sjoberg, who resigned WIR Staff Cardiovascular Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD).

Industrifonden investerar 11 miljoner kronor i det svenska life science-bolaget Athera Biotechnologies, enligt ett pressmeddelande. Athera Biotechnologies AB Athera Biotechnologies AB. Product Development; Solna, Sweden. Advertisement. Join ResearchGate to find the people and research you need to help your STOCKHOLM – Den 19 juni 2013.
Fotografering körkort

It has a proprietary program the fully human antibody PC-mAb. The frim develops a … Athera Biotechnologies AB Follow Following Location: Sweden. Founded in 2005. Private Company " Athera is a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the prevention and treatment of cardiovascular disease.

This market research report provides information about Deals & Alliances (Pharma & Healthcare), Pharma & Healthcare industry. It covers Sweden market data and forecasts. Athera Biotechnologies AB has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
A jensen fluglina

yrsel innan mens
aktionsforskning förskolan
tax services brooklyn
vastar goteborg
surgical precision
anderslovs vardcentral

Styrelseledamot, Athera Biotechnologies AB. Styrelseledamot, Lipidor AB. Styrelseledamot, Nanexa AB. Styrelseledamot, Pharmor AB. Styrelseledamot, Isles of

The Company researches the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease.